(CYRX) Cryoport - Overview

Sector: Industrials | Industry: Integrated Freight & Logistics | Exchange: NASDAQ (USA) | Market Cap: 439m USD | Total Return: 59.7% in 12m

Stock Logistics, Storage, Freezers, Systems, Services
Total Rating 40
Safety 30
Buy Signal 0.40
Integrated Freight & Logistics +4.6
Health Care Equipment -4.4
Market Cap: 439m
Avg Trading Vol: 3.58M USD
ATR: 5.28%
Peers RS (IBD): 71.8
Risk 5d forecast
Volatility71.9%
Rel. Tail Risk-17.3%
Reward TTM
Sharpe Ratio0.78
Alpha25.59
Character TTM
Beta1.012
Beta Downside1.570
Drawdowns 3y
Max DD80.33%
CAGR/Max DD-0.32
EPS (Earnings per Share) EPS (Earnings per Share) of CYRX over the last years for every Quarter: "2021-03": -0.13, "2021-06": -0.16, "2021-09": -0.18, "2021-12": -0.11, "2022-03": -0.31, "2022-06": -0.23, "2022-09": -0.15, "2022-12": -0.24, "2023-03": -0.16, "2023-06": -0.42, "2023-09": -0.31, "2023-12": -1.31, "2024-03": -0.43, "2024-06": -0.29, "2024-09": -0.02, "2024-12": -0.4271, "2025-03": -0.3836, "2025-06": -0.28, "2025-09": -0.18, "2025-12": -0.1712, "2026-03": 0,
EPS CAGR: 5.17%
EPS Trend: 16.3%
Last SUE: 1.36
Qual. Beats: 1
Revenue Revenue of CYRX over the last years for every Quarter: 2021-03: 53.284, 2021-06: 56.191, 2021-09: 56.693, 2021-12: 56.44, 2022-03: 52.302, 2022-06: 64.153, 2022-09: 60.464, 2022-12: 60.358, 2023-03: 62.817, 2023-06: 57.021, 2023-09: 56.157, 2023-12: 57.26, 2024-03: 37.291, 2024-06: 39.709, 2024-09: 56.664, 2024-12: 59.532, 2025-03: 41.04, 2025-06: 45.454, 2025-09: 44.233, 2025-12: 45.45, 2026-03: null,
Rev. CAGR: -3.68%
Rev. Trend: -60.1%
Last SUE: 0.24
Qual. Beats: 0
Risks
Technicals: volatile
Description: CYRX Cryoport

Cryoport Inc. (CYRX) provides temperature-controlled supply chain solutions for the life sciences sector. This includes biopharma/pharma, animal health, and reproductive medicine markets.

The company operates through two segments: Life Sciences Services and Life Sciences Products. The services segment focuses on temperature-controlled logistics and cryogenic biostorage. The products segment offers cryogenic freezers, dewars, and related accessories. The biopharma cold chain logistics market is critical for maintaining the integrity of sensitive biological materials, such as cell and gene therapies.

Cryoports offerings include specialized shipping systems like Cryoport Express Shippers, monitoring systems, and comprehensive biostorage services including sample management and drug product release. They also provide apheresis/leukapheresis collection and cryopreservation services. This integrated approach addresses the complex logistical needs of the life sciences industry.

For a deeper dive into CYRXs performance metrics and competitive landscape, consider exploring ValueRays detailed reports.

Headlines to Watch Out For
  • Biopharma logistics demand drives revenue growth
  • Biostorage services expand market share
  • Cryogenic product sales impact profitability
  • Regulatory changes affect cold chain compliance
  • Global economic slowdown reduces R&D spending
Piotroski VR‑10 (Strict) 2.5
Net Income: 77.7m TTM > 0 and > 6% of Revenue
FCF/TA: -0.03 > 0.02 and ΔFCF/TA 1.44 > 1.0
NWC/Revenue: 146.0% < 20% (prev 143.4%; Δ 2.58% < -1%)
CFO/TA -0.01 > 3% & CFO -8.58m > Net Income 77.7m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 2.17 > 1.5 & < 3
Outstanding Shares: last quarter (49.8m) vs 12m ago 0.29% < -2%
Gross Margin: 47.14% > 18% (prev 0.44%; Δ 4.67k% > 0.5%)
Asset Turnover: 23.99% > 50% (prev 27.46%; Δ -3.47% > 0%)
Interest Coverage Ratio: -14.98 > 6 (EBITDA TTM -7.65m / Interest Expense TTM 2.36m)
Altman Z'' -3.82
A: 0.34 (Total Current Assets 476.2m - Total Current Liabilities 219.0m) / Total Assets 765.0m
B: -0.90 (Retained Earnings -688.9m / Total Assets 765.0m)
C: -0.05 (EBIT TTM -35.4m / Avg Total Assets 734.2m)
D: -2.64 (Book Value of Equity -692.3m / Total Liabilities 262.4m)
Altman-Z'' Score: -3.82 = D
Beneish M -3.39
DSRI: 0.80 (Receivables 33.4m/45.8m, Revenue 176.2m/193.2m)
GMI: 0.94 (GM 47.14% / 44.20%)
AQI: 0.67 (AQ_t 0.21 / AQ_t-1 0.32)
SGI: 0.91 (Revenue 176.2m / 193.2m)
TATA: 0.11 (NI 77.7m - CFO -8.58m) / TA 765.0m)
Beneish M-Score: -3.39 (Cap -4..+1) = AA
What is the price of CYRX shares? As of April 06, 2026, the stock is trading at USD 8.77 with a total of 239,000 shares traded.
Over the past week, the price has changed by +11.15%, over one month by +4.90%, over three months by -10.78% and over the past year by +59.74%.
Is CYRX a buy, sell or hold? Cryoport has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy CYRX.
  • StrongBuy: 4
  • Buy: 2
  • Hold: 4
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the CYRX price?
Wallstreet Target Price 13.6 55.2%
Analysts Target Price 13.6 55.2%
CYRX Fundamental Data Overview as of 05 April 2026
P/E Forward = 56.8182
P/S = 2.4924
P/B = 0.9211
Revenue TTM = 176.2m USD
EBIT TTM = -35.4m USD
EBITDA TTM = -7.65m USD
Long Term Debt = 1.09m USD (from longTermDebt, last quarter)
Short Term Debt = 189.8m USD (from shortTermDebt, last quarter)
Debt = 230.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -19.8m USD (from netDebt column, last quarter)
Enterprise Value = 258.6m USD (439.1m + Debt 230.7m - CCE 411.2m)
Interest Coverage Ratio = -14.98 (Ebit TTM -35.4m / Interest Expense TTM 2.36m)
EV/FCF = -9.97x (Enterprise Value 258.6m / FCF TTM -25.9m)
FCF Yield = -10.03% (FCF TTM -25.9m / Enterprise Value 258.6m)
FCF Margin = -14.72% (FCF TTM -25.9m / Revenue TTM 176.2m)
Net Margin = 44.11% (Net Income TTM 77.7m / Revenue TTM 176.2m)
Gross Margin = 47.14% ((Revenue TTM 176.2m - Cost of Revenue TTM 93.1m) / Revenue TTM)
Gross Margin QoQ = 47.77% (prev 48.21%)
Tobins Q-Ratio = 0.34 (Enterprise Value 258.6m / Total Assets 765.0m)
Interest Expense / Debt = 0.27% (Interest Expense 634k / Debt 230.7m)
Taxrate = 21.0% (US default 21%)
NOPAT = -27.9m (EBIT -35.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.17 (Total Current Assets 476.2m / Total Current Liabilities 219.0m)
Debt / Equity = 0.46 (Debt 230.7m / totalStockholderEquity, last quarter 502.6m)
 Debt / EBITDA = 2.58 (negative EBITDA) (Net Debt -19.8m / EBITDA -7.65m)
 Debt / FCF = 0.76 (negative FCF - burning cash) (Net Debt -19.8m / FCF TTM -25.9m)
 Total Stockholder Equity = 453.9m (last 4 quarters mean from totalStockholderEquity)
RoA = 10.58% (Net Income 77.7m / Total Assets 765.0m)
RoE = 17.12% (Net Income TTM 77.7m / Total Stockholder Equity 453.9m)
RoCE = -7.77% (EBIT -35.4m / Capital Employed (Equity 453.9m + L.T.Debt 1.09m))
 RoIC = -4.41% (negative operating profit) (NOPAT -27.9m / Invested Capital 632.8m)
 WACC = 6.33% (E(439.1m)/V(669.8m) * Re(9.54%) + D(230.7m)/V(669.8m) * Rd(0.27%) * (1-Tc(0.21)))
Discount Rate = 9.54% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 81.65 | Cagr: 1.02%
 [DCF] Fair Price = unknown (Cash Flow -25.9m)
 EPS Correlation: 16.34 | EPS CAGR: 5.17% | SUE: 1.36 | # QB: 1
Revenue Correlation: -60.08 | Revenue CAGR: -3.68% | SUE: 0.24 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-0.17 | Chg7d=+0.017 | Chg30d=-0.019 | Revisions Net=-3 | Analysts=4
EPS current Year (2026-12-31): EPS=-0.65 | Chg7d=+0.060 | Chg30d=+0.000 | Revisions Net=-2 | Growth EPS=+4.2% | Growth Revenue=+8.9%
EPS next Year (2027-12-31): EPS=-0.57 | Chg7d=+0.073 | Chg30d=-0.001 | Revisions Net=-2 | Growth EPS=+12.3% | Growth Revenue=+9.5%
[Analyst] Revisions Ratio: -1.00 (0 Up / 3 Down within 30d for Next Quarter)
External Resources
Dataroma Stockcircle